Market Overview:
The global onychomycosis drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of onychomycosis, rising awareness about available treatment options, and growing demand for topical and oral drugs. Based on type, the global onychomycosis drugs market can be segmented into oral drugs and topical drugs. Oral drugs are further sub-segmented into azoles and allylamines. Topical drugs are further sub-segmented into efinaconazole, tavaborole, ciclopirox olamine, amorolfine hydrochloride nail lacquer 5%, naftifine hydrochloride cream 2%, butenafine hydrochloride cream 1%, terbinafine hydrochloride cream 1%. By application, the global onychomycosis drug market can be segmented into hospital pharmacies, retail pharmacies, online pharmacies.
Product Definition:
Onychomycosis Drugs are a type of antimicrobial drug that is used to treat fungal infections of the nails. Onychomycosis is a relatively common infection that can cause significant pain, dysfunction, and cosmetic concerns. Onychomycosis drugs work by killing or inhibiting the growth of the fungus that causes the infection.
Oral Drugs:
Oral drugs are medications which are taken by mouth. They may be formulated in different ways, such as tablets, capsules or syrups and suspensions. The most commonly used oral drug is the antibiotic medication; however there are many other types of oral drugs available in the market for various diseases and conditions like diabetes, cancer etc.
Topical Drugs:
Onychomycosis is a fungal infection of the nail. It can affect any part of the nail, but most commonly it affects the distal (furthest) portion which is also referred to as the tip of the nail. The cause for onychomycosis is not well understood, but it appears to be an autoimmune process in which antibodies are produced against one or more components of DNA- RNA nucleotides and proteins present in nails.
Application Insights:
Onychomycosis drugs find application in various fields including hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacy segment dominated the market with a share of over 60% in 2017 owing to the high prevalence of onychomycosis patients admitted in hospitals. On the other hand, online and offline pharmacy stores are expected to witness lucrative growth during the forecast period due to increasing consumer preference for purchasing medicines from such stores due to convenience and ease of access.
The demand for onychomycosis drugs is also anticipated to increase among individuals preferring self-medication as these infections are highly prevalent among working class people living in urban areas across developing countries such as India China Brazil Argentina Mexico Chile Colombia etc.
Regional Analysis:
North America dominated the global onychomycosis drugs market in 2017. The presence of key players, favorable reimbursement policies, and availability of effective treatment for onychomycosis are some factors responsible for its large share. Moreover, increasing prevalence of nail-patella syndrome is also expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income and improving healthcare infrastructure in emerging countries such as China and India. Furthermore, an increase in awareness about early diagnosis will also boost revenue generation over this period as patients start seeking treatment at an earlier stage thereby reducing their suffering unnecessarily or undergoing surgery unnecessarily costly procedures that may result ultimately leading to higher medical expenditure associated with it.
Growth Factors:
- Increasing incidence of onychomycosis: The increasing incidence of onychomycosis is one of the key growth drivers for the global onychomycosis drugs market. Onychomycosis is a fungal infection that affects the nails, and it is estimated that around 6-8% of the global population suffers from this condition. This number is expected to grow in future due to various factors such as increasing awareness about onychomycosis, growing aging population, and rising prevalence of diabetes mellitus.
- Rising demand for effective treatment options: The high unmet needs for an effective treatment option for onychomycosis is another key growth driver for the global onychomycosis drugs market. There are currently only a limited number of approved therapies available in this market, which leads to high unmet needs among patients suffering from this condition. This provides ample opportunities for players operating in this market to capitalize on with their innovative products offerings.
- Growing investments by pharmaceutical companies: Pharmaceutical companies are increasingly investing in research and development activities aimed at developing novel therapies for treating various forms of nail fungus infections such as onychomycoses drug pipeline currently consists of more than 50 molecules under different stages clinical development). This will help fuel growth prospectsfortheglobalonycho mycosisdrugsmarketinthefuture . 4 Emerging markets offer lucrative opportunities: The emerging markets offer lucrative opportunities owing to their
Scope Of The Report
Report Attributes
Report Details
Report Title
Onychomycosis Drugs Market Research Report
By Type
Oral Drugs, Topical Drugs
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Pfizer, Novartis, Johnson & Johnson, Bausch Health, Bayer, Galderma, Moberg Pharma, Cipla, Biofrontera, Leo Pharma, Dr. Reddy's Laboratories, Medimetriks Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
207
Number of Tables & Figures
145
Customization Available
Yes, the report can be customized as per your need.
Global Onychomycosis Drugs Market Report Segments:
The global Onychomycosis Drugs market is segmented on the basis of:
Types
Oral Drugs, Topical Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- Johnson & Johnson
- Bausch Health
- Bayer
- Galderma
- Moberg Pharma
- Cipla
- Biofrontera
- Leo Pharma
- Dr. Reddy's Laboratories
- Medimetriks Pharmaceuticals
Highlights of The Onychomycosis Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral Drugs
- Topical Drugs
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Onychomycosis Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Onychomycosis drugs are medications used to treat fungal infections of the skin, including onychomycosis. These medications work by killing the fungus that is causing the infection.
Some of the major players in the onychomycosis drugs market are Pfizer, Novartis, Johnson & Johnson, Bausch Health, Bayer, Galderma, Moberg Pharma, Cipla, Biofrontera, Leo Pharma, Dr. Reddy's Laboratories, Medimetriks Pharmaceuticals.
The onychomycosis drugs market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Onychomycosis Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Onychomycosis Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Onychomycosis Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Onychomycosis Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Onychomycosis Drugs Market Size & Forecast, 2018-2028
4.5.1 Onychomycosis Drugs Market Size and Y-o-Y Growth
4.5.2 Onychomycosis Drugs Market Absolute $ Opportunity
Chapter 5 Global Onychomycosis Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Onychomycosis Drugs Market Size Forecast by Type
5.2.1 Oral Drugs
5.2.2 Topical Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Onychomycosis Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Onychomycosis Drugs Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Onychomycosis Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Onychomycosis Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Onychomycosis Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Onychomycosis Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Onychomycosis Drugs Market Size Forecast by Type
9.6.1 Oral Drugs
9.6.2 Topical Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Onychomycosis Drugs Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Onychomycosis Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Onychomycosis Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Onychomycosis Drugs Market Size Forecast by Type
10.6.1 Oral Drugs
10.6.2 Topical Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Onychomycosis Drugs Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Onychomycosis Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Onychomycosis Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Onychomycosis Drugs Market Size Forecast by Type
11.6.1 Oral Drugs
11.6.2 Topical Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Onychomycosis Drugs Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Onychomycosis Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Onychomycosis Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Onychomycosis Drugs Market Size Forecast by Type
12.6.1 Oral Drugs
12.6.2 Topical Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Onychomycosis Drugs Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Onychomycosis Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Onychomycosis Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Onychomycosis Drugs Market Size Forecast by Type
13.6.1 Oral Drugs
13.6.2 Topical Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Onychomycosis Drugs Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Onychomycosis Drugs Market: Competitive Dashboard
14.2 Global Onychomycosis Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 Johnson & Johnson
14.3.4 Bausch Health
14.3.5 Bayer
14.3.6 Galderma
14.3.7 Moberg Pharma
14.3.8 Cipla
14.3.9 Biofrontera
14.3.10 Leo Pharma
14.3.11 Dr. Reddy's Laboratories
14.3.12 Medimetriks Pharmaceuticals
